Wednesday’s Midday Stock Update: Samsung Electronics (SSNLF), Novavax (NVAX), ImmunoCellular Therapeutics (IMUC), Ocwen Financial (OCN), Frontier Communications Corporation (FTR)

So far Wednesday, August 14, NASDAQ is down -4.48% and the S&P is down -3.67%. Here are this morning’s most active stocks: Samsung Electronics (SSNLFResearch Report), Novavax (NVAXResearch Report), ImmunoCellular Therapeutics (IMUCResearch Report), Ocwen Financial (OCNResearch Report) and Frontier Communications Corporation (FTRResearch Report).

Samsung Electronics is up 44.2% in midday trading to $44.20. Shares opened today at $0.00. The company has a 52-week low of $44.20 and a 52-week high of $2210.00.

Novavax is up 36.91% in midday trading to $6.12. Shares opened today at $4.47. The company has a 52-week low of $4.01 and a 52-week high of $51.60. On the Street’s front, the average 12-month analyst price target for the stock is $29.88, marking a 568.46% potential upside from current levels. In a report released today, H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on NVAX, with a price target of $17, which implies an upside of 280% from current levels.

ImmunoCellular Therapeutics is down -23.53% in midday trading to $0.02. Shares opened today at $0.03. The company has a 52-week low of $0.01 and a 52-week high of $0.25.

See today’s analyst top recommended stocks >>

Ocwen Financial is down -13.16% in midday trading to $1.49. Shares opened today at $1.71. The company has a 52-week low of $1.20 and a 52-week high of $4.35. In the last 30 days, insiders purchased $571.7K worth of OCN shares. Over the last 3 months, the insider sentiment on Ocwen Financial has been positive based on 28 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Frontier Communications Corporation is down -10.36% in midday trading to $0.68. Shares opened today at $0.76. The company has a 52-week low of $0.67 and a 52-week high of $7.25. On the Street’s front, the average 12-month analyst price target for the stock is $0.94, marking a 23.68% potential upside from current levels. In a report issued on August 7, Guggenheim analyst Mike McCormack maintained a Sell rating on FTR, with a price target of $0.50, which represents a potential downside of 34% from where the stock is currently trading. Separately, on the same day, RBC’s Kutgun Maral assigned a Hold rating to the stock and has a price target of $1.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.